Navigation Links
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
Date:4/22/2009

Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix

DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented non-clinical data at the annual meeting of the American Association for Cancer Research (AACR). These non-clinical data indicate that after Micromet developed BiTE antibodies from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) (panitumumab) they were highly active against KRAS-and BRAF-mutated human colorectal cancer cell lines(1). Recent clinical studies have shown that the chimeric monoclonal antibodies cetuximab(2,3) and panitumumab(3,4) are not active in colorectal cancer patients with tumor cells harboring mutations in KRAS and BRAF oncogenes. These two populations make up more than 40% of colorectal cancer patients.

Micromet's researchers converted cetuximab and panitumumab into novel bispecific antibodies based on Micromet's proprietary BiTE technology. Both of Micromet's EGFR BiTE antibodies were able to direct T cells against cetuximab/panitumumab-resistant human colorectal cancer cells harboring KRAS and BRAF mutations, resulting in the destruction of these cancer cells. In mice, daily EGFR BiTE antibody doses as low as 0.1 microgram/kilogram were sufficient to prevent tumor growth from mutated human colorectal cancer cells. Studies in a relevant non-human primate species suggest that active serum levels of the cetuximab-based BiTE antibody are tolerated.

"The data show that our BiTE technology can overcome significant limitations of conventional monoclonal antibodies," commented Patrick Baeuerle, Chief Scientific
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
(Date:8/27/2015)... -- According to a new market research report "Medical ... Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End ... the Medical Lifting Sling Market is poised to reach USD 706.0 ... CAGR of 11.4 % from 2015 to 2020. ... T ables and 65 F ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2011 Reportlinker.com announces that a new market ... Gastric Cancer - Global Drug Forecasts ... 2011 http://www.reportlinker.com/p0479813/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I-2011.html ... Treatment Analysis to 2020 – Volume I 2011 ...
... April 12, 2011 Reportlinker.com announces that a new ... Bladder Cancer - Global Drug Forecasts and ... http://www.reportlinker.com/p0479812/Bladder-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020---Volume-1-2011.html Bladder Cancer ... - Volume 1 2011 Summary ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 2Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 3Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 4Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 5Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 6Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 7Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 8Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 9Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 10Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 11Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 12Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 13Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 14Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 15Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 16Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 17Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 18Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 19Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 20Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 21Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 22Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 2Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 3Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 4Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 5Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 6Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 7Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 8Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 9Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 10Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 11Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 12Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 13Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 14Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 15
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring ... area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... research to improve treatment outcomes. This localized treatment seems to address the ...
(Date:8/28/2015)... ... 28, 2015 , ... Joining a growing number of hospitals ... management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA provides ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th by ... has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from ... several months, but the current process, having already gone on for over a year, ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2
... youths surveyed aren,t smoking to get high, , , FRIDAY, April ... just for recreation but to self-medicate emotional problems, sleep difficulties ... interviews with 63 adolescents who smoked marijuana regularly. About a ... a medication rather than as a means of getting high. ...
... Researchers from the Children,s Cancer Hospital at The University ... how to turn off a certain receptor that promotes ... presented today in a platform session at the 22nd ... (ASPHO). , "There is a certain receptor we now ...
... NORCROSS, Ga., April 24 Immucor, Inc. (Nasdaq: ... instrument-reagent systems to the blood transfusion industry, today announced ... Department of Justice, Antitrust Division, requesting documents for the ... to an investigation of possible violations of the federal ...
... half of all deaths stem from treatable conditions, study ... or treatable health conditions account for nearly 70 percent ... whites in the United States, a new study shows. ... than 65 are caused by preventable or treatable conditions ...
... Message of Hope Considered ,Too Important Not To Be ... announced today that "Light of Hope: Help for Children ... recovery, will debut internationally on Friday, April 24, Saturday, ... www.findingthewords.org during the final week of World ...
... Actions Implemented During 2008 Position the Company for Future, ... Exchange: NVC,VANCOUVER, April 24 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: ... December 31, 2008. , "The fundamental changes Neovasc implemented ... we believe they have resulted in a lean and ...
Cached Medicine News:Health News:Marijuana Is Option to Unpleasant Meds, Teens Say 2Health News:Researchers find drug that inhibits acute leukemia cell growth 2Health News:Racial Disparity in Death Rate May Be Avoidable 2Health News:'Light of Hope: Help for Children with Autism' Ground-Breaking Internet Television Event on April 24 to April 26 Co-Sponsored by Internet Software Leaders 2Health News:'Light of Hope: Help for Children with Autism' Ground-Breaking Internet Television Event on April 24 to April 26 Co-Sponsored by Internet Software Leaders 3Health News:Neovasc Inc. Reports Year 2008 Financial Results 2Health News:Neovasc Inc. Reports Year 2008 Financial Results 3Health News:Neovasc Inc. Reports Year 2008 Financial Results 4Health News:Neovasc Inc. Reports Year 2008 Financial Results 5Health News:Neovasc Inc. Reports Year 2008 Financial Results 6Health News:Neovasc Inc. Reports Year 2008 Financial Results 7Health News:Neovasc Inc. Reports Year 2008 Financial Results 8Health News:Neovasc Inc. Reports Year 2008 Financial Results 9Health News:Neovasc Inc. Reports Year 2008 Financial Results 10Health News:Neovasc Inc. Reports Year 2008 Financial Results 11Health News:Neovasc Inc. Reports Year 2008 Financial Results 12Health News:Neovasc Inc. Reports Year 2008 Financial Results 13
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
Medicine Products: